Literature DB >> 27189457

Prognostic implications of reproductive and lifestyle factors in ovarian cancer.

Elizabeth M Poole1, Panagiotis A Konstantinopoulos2, Kathryn L Terry3.   

Abstract

INTRODUCTION: Despite strides in identifying factors that predict risk of ovarian cancer and improvements in ovarian cancer treatment, little is known about factors that predict ovarian cancer survival.
METHODS: We reviewed the literature for analyses of factors before, at, or after diagnosis that may predict survival outcomes, including demographics (e.g., age and race), genetics (e.g., inherited BRCA mutations), hormonal factors (e.g., parity and hormone use), and lifestyle (e.g., physical activity and diet).
RESULTS: While treatment factors, tumor characteristics and genetic syndromes are predictive of survival, few studies of most hormonal and lifestyle factors have been published; most have evaluated pre-diagnosis factors. For example, we identified eight studies that examined menopausal hormone use prior to diagnosis, reporting a non-significant survival benefit for users compared to non-users, while four studies reported better survival with use after surgery, though only two were significant. Similarly, while increased body size has been extensively studied as potentially associated with reduced survival, other modifiable factors, such as diet and physical activity remain understudied. We identified three studies of pre-diagnosis physical activity and five studies of pre-diagnosis diet, with a suggestive benefit of higher vegetable intake and vigorous physical activity. By contrast, large studies of the impact of race/ethnicity and socioeconomic status (SES) confirm that non-white women and women of lower SES fare more poorly than white women and women of higher SES, respectively.
CONCLUSIONS: Our review of the published literature on predictors of ovarian cancer survival revealed that modifiable lifestyle factors may be related to survival, but that hormonal factors do not strongly predict outcomes in ovarian cancer patients. However, more attention should be paid to women's post-diagnosis survival experience. The dearth of literature on post-diagnosis factors that may improve outcomes makes it difficult to make specific recommendations for survivors.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Lifestyle; Ovarian cancer; Prognosis; Reproductive; Survival

Mesh:

Year:  2016        PMID: 27189457     DOI: 10.1016/j.ygyno.2016.05.014

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  12 in total

Review 1.  Association between Cigarette Smoking and Histotype-Specific Epithelial Ovarian Cancer: A Review of Epidemiologic Studies.

Authors:  Aili Zhou; Albina N Minlikeeva; Sadat Khan; Kirsten B Moysich
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-05-01       Impact factor: 4.254

2.  Mortality by occupation-based social class in Italy from 2012 to 2014.

Authors:  Paola Bertuccio; Gianfranco Alicandro; Gabriella Sebastiani; Nicolas Zengarini; Giuseppe Costa; Carlo La Vecchia; Luisa Frova
Journal:  Int J Public Health       Date:  2018-07-26       Impact factor: 3.380

3.  Epidemiologic paradigms for progress in ovarian cancer research.

Authors:  Shelley S Tworoger; Jennifer Anne Doherty
Journal:  Cancer Causes Control       Date:  2017-05       Impact factor: 2.506

4.  A BRCA1 Splice Site Variant Responsible for Familial Ovarian Cancer in a Han-Chinese Family.

Authors:  Peng-Zhi Hu; Xiang-Yu Chen; Wei Xiong; Zhi-Jian Yang; Xiao-Rong Li; Wen-Zhi Deng; Li-Na Gong; Hao Deng; La-Mei Yuan
Journal:  Curr Med Sci       Date:  2022-03-15

5.  A Follow-Up Study of Ovarian Cancer (OOPS): A Study Protocol.

Authors:  Ting-Ting Gong; Fang-Hua Liu; Ya-Shu Liu; Shi Yan; He-Li Xu; Xin-Hui He; Yi-Fan Wei; Xue Qin; Song Gao; Yu-Hong Zhao; Qi-Jun Wu
Journal:  Front Nutr       Date:  2022-06-16

Review 6.  Current Gaps in Ovarian Cancer Epidemiology: The Need for New Population-Based Research.

Authors:  Jennifer A Doherty; Allan Jensen; Linda E Kelemen; Celeste L Pearce; Elizabeth Poole; Joellen M Schildkraut; Kathryn L Terry; Shelley S Tworoger; Penelope M Webb; Nicolas Wentzensen
Journal:  J Natl Cancer Inst       Date:  2017-10-01       Impact factor: 13.506

7.  Ovarian cancer risk factors by tumor aggressiveness: An analysis from the Ovarian Cancer Cohort Consortium.

Authors:  Renée T Fortner; Elizabeth M Poole; Nicolas A Wentzensen; Britton Trabert; Emily White; Alan A Arslan; Alpa V Patel; V Wendy Setiawan; Kala Visvanathan; Elisabete Weiderpass; Hans-Olov Adami; Amanda Black; Leslie Bernstein; Louise A Brinton; Julie Buring; Tess V Clendenen; Agnès Fournier; Gary Fraser; Susan M Gapstur; Mia M Gaudet; Graham G Giles; Inger T Gram; Patricia Hartge; Judith Hoffman-Bolton; Annika Idahl; Rudolf Kaaks; Victoria A Kirsh; Synnove Knutsen; Woon-Puay Koh; James V Lacey; I-Min Lee; Eva Lundin; Melissa A Merritt; Roger L Milne; N Charlotte Onland-Moret; Ulrike Peters; Jenny N Poynter; Sabina Rinaldi; Kim Robien; Thomas Rohan; Maria-José Sánchez; Catherine Schairer; Leo J Schouten; Anne Tjonneland; Mary K Townsend; Ruth C Travis; Antonia Trichopoulou; Piet A van den Brandt; Paolo Vineis; Lynne Wilkens; Alicja Wolk; Hannah P Yang; Anne Zeleniuch-Jacquotte; Shelley S Tworoger
Journal:  Int J Cancer       Date:  2019-01-14       Impact factor: 7.396

8.  Prospective Analyses of Lifestyle Factors Related to Energy Balance and Ovarian Cancer Risk by Infiltration of Tumor-Associated Macrophages.

Authors:  Naoko Sasamoto; Tianyi Wang; Mary K Townsend; Jonathan L Hecht; A Heather Eliassen; Mingyang Song; Kathryn L Terry; Shelley S Tworoger; Holly R Harris
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-03-02       Impact factor: 4.090

9.  Reproductive and hormonal factors in relation to survival and platinum resistance among ovarian cancer cases.

Authors:  Amy L Shafrir; Ana Babic; Rulla M Tamimi; Bernard A Rosner; Shelley S Tworoger; Kathryn L Terry
Journal:  Br J Cancer       Date:  2016-10-04       Impact factor: 7.640

10.  Roflumilast restores cAMP/PKA/CREB signaling axis for FtMt-mediated tumor inhibition of ovarian cancer.

Authors:  Shipeng Gong; Yongning Chen; Fanliang Meng; Yadi Zhang; Huan Wu; Fei Wu
Journal:  Oncotarget       Date:  2017-12-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.